Patents by Inventor Felix Rey

Felix Rey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11926648
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: March 12, 2024
    Assignees: INSTITUT PASTEUR, IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Felix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Publication number: 20210355167
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.
    Type: Application
    Filed: April 27, 2021
    Publication date: November 18, 2021
    Inventors: Felix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Patent number: 11111274
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus, optionally dengue virus and/or zika envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer, covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or covalently stabilized by linking the two sE monomers through modified sugars; and/or, wherein the
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 7, 2021
    Assignees: INSTITUT PASTEUR, IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Félix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Publication number: 20190256560
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus, optionally dengue virus and/or zika envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer, covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or covalently stabilized by linking the two sE monomers through modified sugars; and/or, wherein the
    Type: Application
    Filed: June 9, 2017
    Publication date: August 22, 2019
    Inventors: Félix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Patent number: 10213413
    Abstract: The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 26, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA RECHERCHEAGRONOMIQUE, Institut Pasteur, UNIVERSITÉ PARIS-SUD
    Inventors: Christina Sizun, Stéphane Duquerroy, Jean-François Eleouet, Felix Rey, Anny Slama Schwok, Didier Desmaele, Patrick Couvreur, Bogdan Tarus
  • Publication number: 20170360752
    Abstract: The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 21, 2017
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA RECHERCHEAGRONOMIQUE, Institut Pasteur, UNIVERSITÉ PARIS-SUD
    Inventors: Christina Sizun, Stéphane Duquerroy, Jean-François Eleouet, Felix Rey, Anny Slama Schwok, Didier Desmaele, Patrick Couvreur, Bogdan Tarus
  • Publication number: 20090275499
    Abstract: The secretion or biological activity of Flaviviruses, as well as the biological activity of NS1 protein from Flavivirus-infected cells, can be inhibited by contacting the cells or the protein with cholesterol inhibitors, sphingolipid inhibitors, glycosphingolipid inhibitors, or molecules comprising an amphipathic, amphiphilic, or hydrophobic region which interacts with NS1 protein.
    Type: Application
    Filed: February 26, 2009
    Publication date: November 5, 2009
    Inventors: Marie Flamand, Jerome Salmon, Felix Rey, Irina Gutsche, Myriam Ermonval, Samer Kayal